{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024714","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.235408+00:00","generated_at":"2026-05-17T21:10:32.827047+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mesa Laboratories Reports First Quarter Fiscal 2026 Results","bullets":["Total revenues increased 2.4% to $59,543,000 for the quarter ended June 30, 2025.","Operating income decreased 45.1% to $3,064,000, impacted by FX and stock-based compensation.","Clinical Genomics division revenue fell 10.7% core organic as China revenues contracted 69%.","About $1.5M of expected Biopharmaceutical Development revenues shifted from Q1 to Q2 due to tariff surcharges.","Non-GAAP adjusted operating income (excluding unusual items) was $12,902, down 15.9% year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024714","json":"https://secwatch.observer/filing/0001437749-25-024714.json","markdown":"https://secwatch.observer/filing/0001437749-25-024714.md","text":"https://secwatch.observer/filing/0001437749-25-024714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774925024714/0001437749-25-024714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774925024714/mlab20250804_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T21:10:32.827047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}